No data required. Just define your TPP and Enki does the rest. Enki is an ensemble of generative algorithms trained on decades worth of experimental data with proven results.
Select your on-target(s), off-target(s),
and other properties in minutes.
Founded in September 2019, we are a team of experienced AI/machine learning researchers and medicinal and computational chemists applying state of the art generative AI to drug discovery in close collaboration with biopharmaceutical partners to redefine the unit economics of drug discovery and development.
We are a team of experienced AI/machine learning and business specialists applying state of the art generative AI to drug discovery in close collaboration with biopharmaceutical partners to bring new therapeutics to market across disease areas and positively impact lives.
Handol Kim
Mehran Khodabandeh
Peter Guzzo
Roslynn Drewitt-Lange
Marshall Drew-Brook
Jason Rolfe
Artem Cherkasov
Ali Saberali
Ahmad Issa
Frank Chang
Board Member
Robert N. Young
PhD, SAB Member (Medicinal Chemistry)
Alexander Tropsha
PhD, SAB Member (Cheminformatics)
Nancy Harrison
Advisor (Strategy/ Commercial)
Jennifer Hamilton
PhD, Advisor (Strategy/Commercial)
Todd Farrell
Advisor (Strategy)
John Boylan
PhD, SAB Member (Cell Biology/Oncology drug discovery)
Mads Daugaard
PhD, SAB Member (Oncology Biology)
Founded in September 2019, we are a team of experienced AI/machine learning and business specialists applying state of the art generative AI to drug discovery in close collaboration with biopharmaceutical partners to bring new therapeutics to market across disease areas and positively impact lives.
Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, today announced a project with Merck Research Labs supported by the CQDM Quantum Leap program.
Variational AI, developer of the Enki™ generative artificial intelligence (AI) drug discovery platform to redefine the economics of drug development, today announced that the company has filed two provisional patents…
Variational AI, developer of generative AI-based drug discovery platform for novel kinase inhibitors, today announced that it has added industry and scientific leader Jennifer Hamilton, Ph.D. as a company advisor.
Please see open job listing below or contact us if you would like to join the team in the area of machine learning, computational medicinal chemistry, and business development.